As fears of a tech bubble and stretched valuations change into the discuss of the city, buyers are turning to Wall Avenue titans for steering, particularly Ken Griffin. Founding hedge fund Citadel in 1990, the agency now boasts over $35 billion price of property beneath administration.As a 19-year-old sophomore at Harvard College, Griffin started buying and selling from his dorm room with a fax machine, pc and telephone. Now, the CEO of Citadel, whose web price stands at $15.5 billion, is called one of many Wall Avenue greats. Wanting on the fund’s efficiency throughout the COVID disaster, it’s much more clear why Griffin has legendary standing.In contrast to the common hedge fund, which had a destructive return of between 3-4% within the first half of 2020, Citadel’s flagship Wellington fund noticed its returns land between 13-14% for a similar interval.Bearing this in thoughts, we needed to take a better take a look at three shares Citadel snapped up just lately. Utilizing TipRanks’ database, we discovered that every ticker has earned a “Robust Purchase” consensus score from the analyst neighborhood. To not point out all three of them boast large upside potential.AVEO Prescription drugs (AVEO)Hoping to offer higher outcomes for sufferers, AVEO Prescription drugs advances focused medicines for oncology and different unmet medical wants. Following an essential regulatory milestone, it’s no surprise all eyes are on this healthcare title.Griffin is amongst these singing AVEO’s praises. Rising its holding by a whopping 2,357%, Citadel purchased up 383,720 shares in Q2. With the entire place now touchdown at 400,003 shares, it’s valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds buyers that on June 1, the FDA accepted the NDA for tivozanib, the corporate’s lead candidate, for assessment, based mostly on the truth that the TIVO-Three examine reported optimistic last general survival (OS) information. Within the examine, AVEO’s remedy was in comparison with sorafenib, marketed as Nexavar by Bayer, for the remedy of superior renal cell carcinoma (RCC) within the third and fourth-line settings.Wanting extra carefully on the information, which was offered on the ASCO 2020 digital assembly, the ultimate OS evaluation resulted in an general hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was “inspired” by the OS outcomes as they “counsel tivozanib at the very least has an analogous general relative danger of deaths in comparison with sorafenib.”“Contemplating that TIVO-Three examine met each the first endpoint of development free survival (PFS) and the secondary endpoint of general response fee (ORR), with comparable OS to the energetic comparator, we consider tivozanib would probably get a inexperienced gentle for the U.S. approval, which may very well be a significant catalyst within the subsequent 12 months,” Ramakanth opined.Including to the excellent news, the dose escalation for the Part 1b/2 DEDUCTIVE examine, evaluating tivozanib together with durvalumab, a monoclonal antibody in opposition to PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Part 2. Because the CDC estimates about 33,000 sufferers undergo from liver most cancers yearly within the U.S., Ramakanth sees a further alternative.To this finish, Ramakanth charges AVEO a Purchase score together with a $12 value goal. Ought to his thesis play out, a possible twelve-month acquire of 163% may very well be within the playing cards. (To observe Ramakanth’s monitor report, click on right here)Different analysts don’t beg to vary. Three Purchase scores and no Holds or Sells have been assigned within the final three months. So, the phrase on the Avenue is that AVEO is a Robust Purchase. The $15 common value goal is extra aggressive than Ramakanth’s and implies 229% upside potential. (See AVEO inventory evaluation on TipRanks)IDEAYA Biosciences (IDYA)Subsequent up we now have IDEAYA Biosciences, an oncology-focused precision medication firm that develops focused therapeutics by utilizing molecular diagnostics. Primarily based on the power of its expertise, this title has scored a number of followers.Reflecting a brand new place for Griffin’s Citadel, the fund pulled the set off on 248,005 shares in Q2. As for the worth of this holding, it is available in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are “undervalued based mostly on the long run potential of its precision medication oncology pipeline, which targets particular biomarkers.” Expounding on this, he said, “IDEAYA is making use of its capabilities throughout a number of courses of precision medication, together with direct focusing on of oncogenic pathways and artificial lethality – which represents an rising class of precision medication targets.”A part of what makes IDYA a stand-out, in Chiang’s opinion, is the truth that its preclinical applications use its artificial lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) together with BRCA mutations.“We consider the longer-term upside potential with IDYA shares is critical given the potential utility of SL. The primary clinically validated SL gene pair was PARP-BRCA1/2, and based mostly on the efficacy of PARP inhibitors, the SL method to treating most cancers has achieved substantial industrial validation,” the analyst defined.To again this up, Chiang factors out that a number of PARP inhibitors have already been permitted for the remedy of tumors with BRCA and different DNA harm restore alterations, together with ovarian, breast and pancreatic cancers. These inhibitors embody AstraZeneca’s olaparib, GlaxoSmithKline’s niraparib, Pfizer’s talazoparib and Clovis’ rucaparib. He added, “We estimate these 4 medication generated over $1.6 billion in worldwide gross sales in 2019 and are anticipated to achieve over $6 billion in gross sales by 2024.”It ought to be famous that a number of IND filings are set to return inside the subsequent 4-12 months, with IDYA’s lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus trigger the loss of life of cancerous tumor cells, coming into the clinic in 2021.It ought to come as no shock, then, that Chiang joined the bulls. To begin off his IDYA protection, he places an Outperform score and $28 value goal on the inventory. This goal implies a attainable twelve-month rise of 141% may very well be on the horizon. (To observe Chiang’s monitor report, click on right here)Equally, the remainder of the Avenue is getting onboard. 5 Purchase scores assigned within the final three months add as much as a Robust Purchase analyst consensus. As well as, the $25.20 common value goal places the potential twelve-month acquire at 116%. (See IDYA inventory evaluation on TipRanks)Ocular Therapeutix (OCUL)Utilizing its patented bioresorbable hydrogel-based formulation expertise, Ocular Therapeutix develops cutting-edge therapies for ailments and situations of the attention. The progress of its medical applications has caught Wall Avenue’s consideration, with some arguing that now’s the time to get in on the motion.Griffin and Citadel didn’t wish to miss out on a possibility. Snapping up 161,032 shares throughout Q2, the hedge fund gave the holding a 272% enhance. The entire place is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to deal with the unmet wants within the dry eye illness indication as a key element of his bullish thesis. The corporate boasts two property focusing on the situation, OTX-CSI (persistent) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine because the energetic drug within the intracanalicular insert, which is launched for an estimated three months to extend tear manufacturing.With regards to OTX-DED, Leone argues OCUL was “intelligent in pursuing the event of OTX-DED (a low dose type of DEXTENZA, a corticosteroid intracanalicular insert positioned within the punctum, a pure opening within the eye lid, and into the canaliculus to ship dexamethasone to the ocular floor for as much as 30 days with out preservatives) for the remedy of episodic dry eye, because the prior security information from the DEXTENZA approval enabled administration to file a Part 2-enabling IND by YE20.”Talking to the attainable alternative right here, each merchandise might “present income era for physicians within the remedy of dry eyes utilizing process CPT code 0356T, which might present incentive for speedy adoption within the dry eye house that’s at present valued at $5.1 billion,” in Leone’s opinion.As for the medical and regulatory pathway, the Part 2 trial for OTX-DED is ready to kick off in 2H21, barely after OTX-CSI, which can see a Part 2 medical trial evaluating two totally different formulations initiated by 4Q20. Primarily based on the brief remedy period of OTX-DED, administration thinks it can nonetheless be delivered to market first.To this finish, Leone stays optimistic concerning the firm’s long-term progress narrative. In consequence, he charges OCUL a Robust Purchase together with a $15 value goal. This determine implies shares might rise 89% within the 12 months forward. (To observe Leone’s monitor report, click on right here) Turning now to the remainder of the Avenue, different analysts are on the identical web page. With 100% Avenue assist, or Three Purchase scores to be actual, the consensus is unanimous: OCUL is a Robust Purchase. The $13.50 common value goal brings the upside potential to 70%. (See OCUL inventory evaluation on TipRanks)To seek out good concepts for shares buying and selling at enticing valuations, go to TipRanks’ Finest Shares to Purchase, a newly launched instrument that unites all of TipRanks’ fairness insights.Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is vitally essential to do your personal evaluation earlier than making any funding.